Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 vs Chemotherapy in HR+/HER2- Breast Cancer
NCT07071337Phase 3Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in breast cancer, sponsored by Kelun-Biotech. Started Jul 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07071337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071337.